Research programme: vitamin D3 analogues - Bayer Healthcare Pharmaceuticals

Drug Profile

Research programme: vitamin D3 analogues - Bayer Healthcare Pharmaceuticals

Alternative Names: Vitamin D3 analogues research programme - Bayer Healthcare; ZK 191784; ZK 203278

Latest Information Update: 21 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class
  • Mechanism of Action Immunosuppressants; Vitamin D3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Immunosuppression

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 29 Mar 2010 Preclinical development is ongoing in Germany
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top